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A major driver of cost growth in health care is the rapid increase in the utilization of existing technology 
and not simply the adoption of new technology.  Health economists and their HTA colleagues have 
become obsessed by technology adoption questions and have largely ignored ‘technology management’ 
questions.  Technology management would include the life-cycle assessment of technologies in use, to 
assess their real-world performance; and monitoring of technology indication creep.  A rebalancing of 
focus might serve to encourage a more self-critical and learning culture amongst those involved in 
technology evaluation analysis.  Further, health economists and health technology assessment analysts 
could make a more significant contribution to system efficiency through rebalancing their efforts away 







The focus of this paper is health care technology (drugs, devices, procedures and screening), and 
specifically its adoption and use in the system.  Our premise is that health economists and their 
colleagues in the health technology assessment (HTA) ‘industry’ have become obsessed by adoption 
questions – i.e., should a new technology be available for routine use in the health care system? – and 
have largely ignored the ‘technology management’ questions – i.e., once in the system, how do we 
ensure cost-effective utilization? 
Our argument is that, in order to achieve the goals of efficiency and equity through technology use, 
much greater analytic emphasis is required on the technology management issue, with analysts breaking 
out of the adoption ‘addiction’. This issue will grow  more and more in importance as entities, such as 
clinical care groups in England and integrated care networks more globally, find that budget restrictions 
mean that service developments cannot simply be ‘added-on’ to their portfolios without consideration 
of from where, within such budgets, the required resources will come.  
Technology as a driver of cost growth 
Total spending on health care in Canada has now passed $200 billion, with annual increases over the last 
decade in the range of 7.4% (Canadian Institute for Health Information, 2011). The rate of growth has 
slowed over the last couple of years but the need to ‘bend back the cost curve’ is the dominant 
conversation amongst health care leaders. Likewise in the UK, expenditure is now well in excess of £100 
billion but year on year growth is slowing to about 1% in real terms going forward. The pattern in 
Canada and the UK mirrors trends in other similar developed nations (Callan et al., 2010).  
The impact of technological change as a cost driver has been difficult to quantify precisely but is widely 
considered to be one of the largest contributors to such growth.   Thus, effective efforts to address cost 
growth cannot ignore technology.  With the pace at which new technologies appear, there is always 
pressure on decision-makers – from patients, providers and manufacturers – to expand public coverage 
for technologies. Both Canada and the UK have long traditions in HTA, with well-established and active 
HTA processes that directly inform adoption decisions.  
Part of the evidence of the need for a rebalancing of effort is the realization that rapid increases in the 
utilization of existing technology (and not simply the adoption of new technology) represent a major 
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driver of cost growth.  For example, Keenan et al. (2007) report that the annual admission rates for 
cataract surgery in England increased 10-fold between 1968 and 2003; from 62 per 100,000 to 637 per 
100,000 in 2004. This increase was not driven primarily by demographic changes; the increase in 
cataract surgery rates was seen in every eligible age group (Keenan et al., 2007).  Similarly, medical 
imaging examinations have seen large utilization increases: in 2010 in Canada, 1.4 million magnetic 
resonance imaging (MRI) examinations and 4.2 million computed tomography (CT) examinations were 
performed, representing annual increases over recent years of 6.9% and 6.2% for MRI and CT, 
respectively (Canadian Institute for Health Information, 2011). 
What issues might be addressed by ‘technology management’? 
(1) Guarding against sub-optimal performance of health technologies 
We see technology management having an emphasis on improvement.  This would translate to a 
role whereby health sector staff and analysts strive for improvement in the quality and cost-
effectiveness of the service being delivered. An example of this improvement-focused economic 
analysis is Turner et al. (2011) who took as their starting point the English National Chlamydia 
Screening Programme and explored, using mathematical modelling, alternative approaches to 
improving the cost-effectiveness of the existing Programme. They conclude that the focus for 
efficiency improvement should be on partner notification strategies rather than increasing male 
screening coverage.  Another example is Richardson et al. (2009) concerned with gastrointestinal 
endoscopy and flexible sigmoidoscopy.  Their analysis was not questioning the use of these 
technologies, which represent established and standard of care practices, but rather sought 
efficiency gains in the delivery of the technology. Specifically, the question was asked whether 
physician or nurse delivered procedures are more cost-effective? Given the cost pressure frame to 
our paper, this ‘scope of practice’ type of question is of great importance.  Interestingly, their 
findings support the higher cost physician-delivered care as being both more effective and cost-
effective. 
 
(2) Indication creep 
A technology management area related to appropriateness is the concern relating to ‘indication 
creep’.  That is, once a new technology has been accepted and adopted for use in one clinical area 
or patient group, the door is often open for its use to spread to other patient groups, without formal 
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consideration of cost-effectiveness.  Indication creep is found in all clinical specialties.  Examples 
indicated by Djulbegovic & Paul (2011) include: 
 Statins – cost-effective in secondary prevention of heart disease but not when used for 
primary prevention in low-risk patients; and 
 Prostate-specific antigen (PSA) test – an important tool for detecting prostate cancer in 
symptomatic patients but of uncertain efficacy in screening asymptomatic patients. 
 
Evidence of such creep does not in itself point to system inefficiencies but it does highlight 
important technology use questions for investigation.  We would want to encourage ‘managed 
creep’, with analysis and monitoring of the impact on service efficiency. This requires the clinical 
community and health economists to work together to develop frameworks for such analysis.   
 
(3) Technologies failing to deliver promised benefits 
Another area of concern (but this time with the analysis-side of the equation) is whether, when a 
technology is implemented into clinical practice, we see the scale of benefits and costs that were 
predicted at the time of adoption.  That is, how good are our analysis-based predictions of costs and 
benefits?  For example, have we seen the predicted health gains, and cost profiles, from the 
widespread use of new cancer or Alzheimer’s drugs?  It seems remarkable that we cannot answer 
such questions with any degree of certainty – we should be testing the predictive validity of our 
analysis work in a more systematic and rigorous manner.  As analysts, we too should be seeking 
improvement – such a learning experience would require understanding the predictive validity of 
our analyses and, where the results are poor, understanding why. 
Pathology 
If the premise is accepted then the question is, why the adoption focus is so prevalent?  Let us consider 
both the demand (the paymasters) and supply (the analysts) sides of technology evaluation work. 
On the demand side, the problem can largely be summed up as ‘he who pays the piper, calls the tune’.  
Funding is more readily available for analysis work focussed on adoption decisions and so it is no 
surprise that we see more activity on that side.  The funding comes from both private and public sector 
sources, and much of it flows in the context of reimbursement decision making.  Those organisations 
with a stake in the technology adoption decision (e.g. pharmaceutical and device manufacturers) 
6 
 
naturally wish to strengthen their product’s claim for reimbursement.  In some jurisdictions, coverage 
decision making agencies mandate that an economic analysis be undertaken before a new technology 
will be appraised. The consequence then is that public bodies such as the National Institute for Health & 
Care Excellence (NICE) require analytic support to allow technology appraisal decisions to be made. 
This is all well and good, and we are not critical of this development in itself, it is the lack of balance 
(between adoption and management analytic activity) that is the concern.  In the field of technology 
appraisal, agencies such as NICE and the Canadian Agency for Drugs and Technologies in Health (CADTH) 
have been largely mandated (by their own paymasters) to focus on adoption.  More naturally one would 
look to health care delivery organisations, charged with delivering safe and effective care to their 
populations whilst remaining within budget, (e.g. health authorities, primary care trusts, etc.) to give 
emphasis to the management issues.  It is, therefore, disappointing, but not surprising, to read Robinson 
et al. (2012): ‘in reality PCT boards focussed more on developing robust priority-setting processes 
around new service developments than other areas.’ The move from prioritising service developments 
to scrutinising whole budget areas needs to involve, or even be led by, clinical care groups and 
integrated care networks, especially as it is clinicians who are the main resource-influencers in any 
health care system. 
On the supply side, health economists and HTA analysts have seen benefits flow in their direction and so 
the response has generally been one of either active or passive encouragement of the adoption focus. 
Why would we want to be playing a different tune?  Our answer is simple: if we do not address this issue 
then the work of health economists might serve to diminish rather than enhance health sector efficiency 
and equity. 
Treatment options 
(1) Life-cycle technology evaluation 
Working in close partnership with health sector decision makers, health economists should 
adopt of model of evaluation and assessment throughout the life cycle of health technologies. 
This speaks to work on development of administrative data systems that allow effective 
monitoring of technology in use in the system. Of course there are substantial resource 
implications in this route that would have to be weighed carefully but the potential benefit – 
greater efficiency and equity in the management of resources – surely would suggest that 
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consideration is, at least, justified. The development of in-service data collection of patient-
reported outcomes, as we see in both England and Canada (Devlin & Appleby, 2010; McGrail et 
al., 2012; Bryan et al., 2012), is a move in this direction. 
 
(2) Decommissioning focus 
As part of routine assessment of existing technologies, there needs to be a much greater focus 
on decommissioning (i.e., disinvestment) of services (Cooper, 2010; Donaldson et al., 2010). The 
track-record on decommissioning, either in terms of stopping ineffective services or scaling back 
of low value services is woeful. Efforts in the UK and Australia suggest relatively low yield on 
targeting purely ineffective services (perhaps because clinical practice naturally evolves away 
from services that are not clinically effective), but opportunities abound on releasing resources 
from effective – but lower value – services (Elshaug et al., 2007). It is here that health 
economists could be making a major contribution to real world decision making, especially given 
the current climate of fiscal constraint.  
 
(3) Assessments of predictive validity 
The final recommendation is for tracking the validity of analysis predictions for the technology 
at the time of coverage.  Fostering a more self-critical and learning culture amongst those 
involved in technology evaluation analysis is critical.  This requires analysts, once the given 
technology is in routine use, to see the value in re-visiting the initial analyses to allow for 
refinement of the application of research methodologies but also on-going (i.e. ‘real time’) 
assessment of true effectiveness in relation to actual costs. 
Conclusion 
The primary symptom we are concerned by is the poor alignment between goals and activity of health 
economists and HTA analysts in the field of technology evaluation. The vast majority of our analytic 
effort in technology evaluation is focused on the adoption decision rather than the system use of 
technologies. This paper is a call for health economists and their collaborators to become more engaged 
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